THBS1 and thyroid gland carcinoma: Routine assessment of pro-metastatic biomarkers, including TSP-1 and integrins, will help monitor patients undergoing targeted therapies, enable earlier metastatic potential of aggressive BRAFV600E-positive human thyroid cancer, foster development of innovative therapies for refractory thyroid cancer to current treatments, and allow improved patient selection for clinical trials.